Impact of metabolic syndrome on pre- and postoperative parameters in patients undergoing a HoLEP surgery.

Abstract

We aimed to investigate the safety and success of the holmium laser enucleation of prostate (HoLEP) surgery in patients with metabolic syndrome (MS) versus those without MS who have similar prostate sizes. Data from 120 patients who underwent HoLEP by a single surgeon between November 2015 and January 2018 were prospectively analyzed. Group 1 (n=40) and Group 2 (n=80) consisted of patients with and without MS, respectively. Preoperative-and postoperative third month control variables that were compared between the groups included hemoglobin (Hb) level; International Prostate Symptom Score (IPSS); uroflowmetry parameters, such as maximum flow rate (Qmax) and average flow rate (Qave); post-voiding residue (PVR); voiding time (VT); and time to maximum flow rate (MVT). For postoperative outcomes between the groups, only hospitalization time (HT) was significant among IPSS, Qmax, Qave, PVR, VT, MVT, Hb decrease, and catheterization time (p=0.03). A multivariate analysis showed that the triglyceride level positively correlated with HT among Group 1 patients (p=0.03). Perioperative outcomes, such as enucleated tissue weight, efficiency of enucleation, enucleation rate, efficiency of morcellation, enucleation time, morcellation time, total operation time, total laser energy, and laser efficiency, were compared as non-significant between the two groups (p>0.05). We found that HoLEP can be considered a safe and effective surgical treatment for patients with MS.